Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at bhoyt@mjhlifesciences.com.
Common Adverse Events With Trastuzumab Deruxtecan for Breast Cancer
Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.
22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers
Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.
Dexamethasone Plus Physical Activity May Reduce Cancer-Related Fatigue
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
Drug Toxicity May Drive Early Niraparib Discontinuation in Ovarian Cancer
Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break